Strategic aspects of NPY-based monoclonal antibodies for diagnosis and treatment of breast cancer.
Identifieur interne : 000047 ( Main/Exploration ); précédent : 000046; suivant : 000048Strategic aspects of NPY-based monoclonal antibodies for diagnosis and treatment of breast cancer.
Auteurs : Drashti Desai ; Pravin ShendeSource :
- Current protein & peptide science [ 1875-5550 ] ; 2020.
Abstract
Immunotherapy emerges as a treatment strategy for breast cancer marker, diagnosis and treatment. In this review, monoclonal antibodies (mAbs)-based passive and peptide vaccines as active immunotherapy approaches like activation of B-cells and T-cells are studied. Passive immunotherapy is mAbs-based therapy effective against tumor cells acts by targeting HER2, IGF 1R, VEGF, BCSC and immune checkpoints. Neuropeptide Y (NPY) and GPCR are the areas of interest to target BC metastases for on-targeting therapeutic action. Neuropeptide S (NPS) or NPS receptor 1 acts as a biomarker for Neuroendocrine tumors (NET), mostly characterized by synaptophysin and chromogranin-A expression or Ki-67 proliferation index. The protein fusion technologies arise as a promising avenue in plant expression systems for increased recombinant Ab accumulation and cost-efficient purification. Recently, mAbs-based immunotherapy effectiveness is appreciated as a novel therapeutic combination of chemotherapy and immunotherapy to reduce the side effects and improve therapeutic responsiveness. Synthetic drug resistance will be overcome by mAbs-based therapy through several clinical trials and detection methods need to be optimized for accuracy and precision. Pharmacokinetic attributes need to be accessed for preferred receptor-agonist activity without ligand accumulation.
DOI: 10.2174/1389203721666200918151604
PubMed: 32951575
Affiliations:
Links toward previous steps (curation, corpus...)
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Strategic aspects of NPY-based monoclonal antibodies for diagnosis and treatment of breast cancer.</title><author><name sortKey="Desai, Drashti" sort="Desai, Drashti" uniqKey="Desai D" first="Drashti" last="Desai">Drashti Desai</name><affiliation><nlm:affiliation>Shobhaben Pratapbhai Patel School of Pharmacy and Technology Management, SVKM'S NMIMS, V. L. Mehta road, Vile Parle (W), Mumbai. India.</nlm:affiliation><wicri:noCountry code="subField">Mumbai</wicri:noCountry></affiliation></author><author><name sortKey="Shende, Pravin" sort="Shende, Pravin" uniqKey="Shende P" first="Pravin" last="Shende">Pravin Shende</name><affiliation><nlm:affiliation>Shobhaben Pratapbhai Patel School of Pharmacy and Technology Management, SVKM'S NMIMS, V. L. Mehta road, Vile Parle (W), Mumbai. India.</nlm:affiliation><wicri:noCountry code="subField">Mumbai</wicri:noCountry></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2020">2020</date><idno type="RBID">pubmed:32951575</idno><idno type="pmid">32951575</idno><idno type="doi">10.2174/1389203721666200918151604</idno><idno type="wicri:Area/Main/Corpus">000047</idno><idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Corpus" wicri:corpus="PubMed">000047</idno><idno type="wicri:Area/Main/Curation">000047</idno><idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Curation">000047</idno><idno type="wicri:Area/Main/Exploration">000047</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Strategic aspects of NPY-based monoclonal antibodies for diagnosis and treatment of breast cancer.</title><author><name sortKey="Desai, Drashti" sort="Desai, Drashti" uniqKey="Desai D" first="Drashti" last="Desai">Drashti Desai</name><affiliation><nlm:affiliation>Shobhaben Pratapbhai Patel School of Pharmacy and Technology Management, SVKM'S NMIMS, V. L. Mehta road, Vile Parle (W), Mumbai. India.</nlm:affiliation><wicri:noCountry code="subField">Mumbai</wicri:noCountry></affiliation></author><author><name sortKey="Shende, Pravin" sort="Shende, Pravin" uniqKey="Shende P" first="Pravin" last="Shende">Pravin Shende</name><affiliation><nlm:affiliation>Shobhaben Pratapbhai Patel School of Pharmacy and Technology Management, SVKM'S NMIMS, V. L. Mehta road, Vile Parle (W), Mumbai. India.</nlm:affiliation><wicri:noCountry code="subField">Mumbai</wicri:noCountry></affiliation></author></analytic><series><title level="j">Current protein & peptide science</title><idno type="eISSN">1875-5550</idno><imprint><date when="2020" type="published">2020</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Immunotherapy emerges as a treatment strategy for breast cancer marker, diagnosis and treatment. In this review, monoclonal antibodies (mAbs)-based passive and peptide vaccines as active immunotherapy approaches like activation of B-cells and T-cells are studied. Passive immunotherapy is mAbs-based therapy effective against tumor cells acts by targeting HER2, IGF 1R, VEGF, BCSC and immune checkpoints. Neuropeptide Y (NPY) and GPCR are the areas of interest to target BC metastases for on-targeting therapeutic action. Neuropeptide S (NPS) or NPS receptor 1 acts as a biomarker for Neuroendocrine tumors (NET), mostly characterized by synaptophysin and chromogranin-A expression or Ki-67 proliferation index. The protein fusion technologies arise as a promising avenue in plant expression systems for increased recombinant Ab accumulation and cost-efficient purification. Recently, mAbs-based immunotherapy effectiveness is appreciated as a novel therapeutic combination of chemotherapy and immunotherapy to reduce the side effects and improve therapeutic responsiveness. Synthetic drug resistance will be overcome by mAbs-based therapy through several clinical trials and detection methods need to be optimized for accuracy and precision. Pharmacokinetic attributes need to be accessed for preferred receptor-agonist activity without ligand accumulation.</div></front></TEI><pubmed><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">32951575</PMID><DateRevised><Year>2020</Year><Month>09</Month><Day>21</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1875-5550</ISSN><JournalIssue CitedMedium="Internet"><PubDate><Year>2020</Year><Month>Sep</Month><Day>18</Day></PubDate></JournalIssue><Title>Current protein & peptide science</Title><ISOAbbreviation>Curr Protein Pept Sci</ISOAbbreviation></Journal><ArticleTitle>Strategic aspects of NPY-based monoclonal antibodies for diagnosis and treatment of breast cancer.</ArticleTitle><ELocationID EIdType="doi" ValidYN="Y">10.2174/1389203721666200918151604</ELocationID><Abstract><AbstractText>Immunotherapy emerges as a treatment strategy for breast cancer marker, diagnosis and treatment. In this review, monoclonal antibodies (mAbs)-based passive and peptide vaccines as active immunotherapy approaches like activation of B-cells and T-cells are studied. Passive immunotherapy is mAbs-based therapy effective against tumor cells acts by targeting HER2, IGF 1R, VEGF, BCSC and immune checkpoints. Neuropeptide Y (NPY) and GPCR are the areas of interest to target BC metastases for on-targeting therapeutic action. Neuropeptide S (NPS) or NPS receptor 1 acts as a biomarker for Neuroendocrine tumors (NET), mostly characterized by synaptophysin and chromogranin-A expression or Ki-67 proliferation index. The protein fusion technologies arise as a promising avenue in plant expression systems for increased recombinant Ab accumulation and cost-efficient purification. Recently, mAbs-based immunotherapy effectiveness is appreciated as a novel therapeutic combination of chemotherapy and immunotherapy to reduce the side effects and improve therapeutic responsiveness. Synthetic drug resistance will be overcome by mAbs-based therapy through several clinical trials and detection methods need to be optimized for accuracy and precision. Pharmacokinetic attributes need to be accessed for preferred receptor-agonist activity without ligand accumulation.</AbstractText><CopyrightInformation>Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.net.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Desai</LastName><ForeName>Drashti</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Shobhaben Pratapbhai Patel School of Pharmacy and Technology Management, SVKM'S NMIMS, V. L. Mehta road, Vile Parle (W), Mumbai. India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shende</LastName><ForeName>Pravin</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Shobhaben Pratapbhai Patel School of Pharmacy and Technology Management, SVKM'S NMIMS, V. L. Mehta road, Vile Parle (W), Mumbai. India.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2020</Year><Month>09</Month><Day>18</Day></ArticleDate></Article><MedlineJournalInfo><Country>United Arab Emirates</Country><MedlineTA>Curr Protein Pept Sci</MedlineTA><NlmUniqueID>100960529</NlmUniqueID><ISSNLinking>1389-2037</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Antigen</Keyword><Keyword MajorTopicYN="N">antibody</Keyword><Keyword MajorTopicYN="N">immunity</Keyword><Keyword MajorTopicYN="N">immunotherapy</Keyword><Keyword MajorTopicYN="N">receptor</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2020</Year><Month>05</Month><Day>09</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2020</Year><Month>08</Month><Day>17</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2020</Year><Month>08</Month><Day>31</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>9</Month><Day>21</Day><Hour>5</Hour><Minute>31</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>9</Month><Day>22</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2020</Year><Month>9</Month><Day>22</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">32951575</ArticleId><ArticleId IdType="pii">CPPS-EPUB-110097</ArticleId><ArticleId IdType="doi">10.2174/1389203721666200918151604</ArticleId></ArticleIdList></PubmedData></pubmed><affiliations><list></list><tree><noCountry><name sortKey="Desai, Drashti" sort="Desai, Drashti" uniqKey="Desai D" first="Drashti" last="Desai">Drashti Desai</name><name sortKey="Shende, Pravin" sort="Shende, Pravin" uniqKey="Shende P" first="Pravin" last="Shende">Pravin Shende</name></noCountry></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Bois/explor/PlantImRecepV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000047 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 000047 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Bois
|area= PlantImRecepV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= pubmed:32951575
|texte= Strategic aspects of NPY-based monoclonal antibodies for diagnosis and treatment of breast cancer.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i -Sk "pubmed:32951575" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd \
| NlmPubMed2Wicri -a PlantImRecepV1
| This area was generated with Dilib version V0.6.38. |  |